Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib + Cisplatin/Pemetrexed in First-Line Non-Squamous NSCLC
NCT00768755Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of axitinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (5 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival up to 84 weeks. Started Jan 2009; status: completed.
02
Drugs
axitinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00768755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768755.